ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > GDF-8

GDF-8

概要

Name:Growth/differentiation factor 8
Target Synonym:MSTN,GDF-8,GDF8,Growth Differentiation Factor 8,MSLHP,Myostatin,Growth/Differentiation Factor 8
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

GDF-8, Myostatin, GDF8, MSTN, Growth/differentiation factor 8

Background

Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Domagrozumab PF-6252616; PF-06252616 Pfizer Inc Details
AAV1-FS344 AAV1-Follistatin; AAV1-FS344 Phase 2 Clinical Nationwide Children'S Hospital Myositis, Inclusion Body; Muscular Dystrophy, Duchenne Details
RO-7204239 GYM-329; RO-7204239; RG-6237; RG-70240 Phase 3 Clinical F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal Details
Apitegromab SRK-015 Phase 3 Clinical Scholar Rock Spinal Muscular Atrophies of Childhood; Neuromuscular Manifestations; Muscular Atrophy; Neuromuscular Diseases; Muscular Atrophy, Spinal; Atrophy Details
Talditercept alfa RO-7239361; BMS-986089; RG-6206; BHV-2000 Phase 3 Clinical Bristol-Myers Squibb Company Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal Details

This web search service is supported by Google Inc.

totopphone